IMMUNITYBIO, INC. Operating Lease, Liability, Noncurrent
IMMUNITYBIO, INC. (IBRX) had Operating Lease, Liability, Noncurrent of $31.20 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability, Noncurrent $31.20M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $33.15M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $33.45M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $34.13M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $31.20M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $33.15M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $33.45M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $34.13M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $35.84M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $33.10M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $34.82M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $36.76M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $36.43M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $38.20M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $39.94M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $39.31M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $44.56M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $46.29M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $47.95M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $49.56M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $50.65M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $36.25M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $37.07M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $34.64M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $29.12M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $16.55M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $16.18M 10-K · filed 2022-03-01 | $9.81M 10-K · filed 2021-03-04 |
| 2020-09-30 | $11.25M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $9.46M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $10.18M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $18.83M 8-K/A · filed 2021-04-22 | $10.88M 10-K · filed 2020-03-25 |
| 2019-09-30 | $11.73M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $12.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $12.75M 10-Q · filed 2019-05-08 | |
| 2019-01-01 | $13.41M 10-K · filed 2020-03-25 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |